ArticlePharmaceuticals (Basel, Switzerland)2024
3D-Printed Plasmonic Nanocomposites: VAT Photopolymerization for Photothermal-Controlled Drug Release.
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Core-Shell Plasmonic Nanocomposites with Synergistic Photothermal and Photochemical Activity for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- Democratization of Point-of-Care Viral Biosensors: Bridging the Gap from Academia to the Clinic.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGold nanoparticles can generate heat upon exposure to radiation due to their plasmonic properties, which depend on particle size and shape. This enables precise control over the release of active substances from polymeric pharmaceutical formulations, minimizing side effects and premature release. The technology of 3D printing, especially vat photopolymerization, is valuable for integrating nanoparticles into complex formulations.
methodThis study aimed to incorporate gold nanospheres (AuNSs) and nanorods (AuNRs) into polymeric matrices using vat photopolymerization, allowing for controlled drug release with exposure to 532 nm and 1064 nm wavelengths.
resultsThe AuNSs (27 nm) responded to 532 nm and the NRs (60 nm length, 10 nm width) responded to 1064 nm. Niclosamide was used as the drug model. Ternary blends of Polyethylene Glycol Diacrylate 250 (PEGDA 250), Polyethylene Glycol 400 (PEG 400), and water were optimized using DesignExpert 11 software for controlled drug release upon specific wavelength exposure. Three matrices, selected based on solubility and printability, underwent rigorous characterization. Two materials achieved controlled drug release with specific wavelengths. Bilayer devices combining AuNSs and AuNRs demonstrated selective drug release based on irradiation wavelength.
conclusionsA pharmaceutical device was developed, capable of controlling drug release upon irradiation, with potential applications in treatments requiring delayed administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.